A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib.
about
Dual inhibitors of hepatitis C virus and hepatocellular carcinoma: design, synthesis and docking studies.Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study.Efficacy and Safety of Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis of Phase III Trials.Patient Selection for Transarterial Chemoembolization in Hepatocellular Carcinoma: Importance of Benefit/Risk Assessment.Extremely High Objective Response Rate of Lenvatinib: Its Clinical Relevance and Changing the Treatment Paradigm in Hepatocellular Carcinoma
P2860
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
A New Era of Systemic Therapy ...... th Regorafenib and Lenvatinib.
@en
A New Era of Systemic Therapy ...... th Regorafenib and Lenvatinib.
@nl
type
label
A New Era of Systemic Therapy ...... th Regorafenib and Lenvatinib.
@en
A New Era of Systemic Therapy ...... th Regorafenib and Lenvatinib.
@nl
prefLabel
A New Era of Systemic Therapy ...... th Regorafenib and Lenvatinib.
@en
A New Era of Systemic Therapy ...... th Regorafenib and Lenvatinib.
@nl
P2860
P356
P1433
P1476
A New Era of Systemic Therapy ...... th Regorafenib and Lenvatinib.
@en
P2093
Masatoshi Kudo
P2860
P304
P356
10.1159/000462153
P577
2017-03-09T00:00:00Z